Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - A phase II study

Gynecologic Oncology

Volumn 112, Issue 2, 2009, Pages 384-388

  Atmaca, Akin ^a   Al Batran, Salah Eddin ^a   Neumann, Antje ^a   Kolassa, Yvonne ^a   Jäger, Dirk ^b   Knuth, Alexander ^c   Jäger, Elke ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b NCT   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Carboplatin; Ovarian cancer; Platinum resistance; Whole body hyperthermia

Indexed keywords

CARBOPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTHERMIA; LEUKOPENIA; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; YOUNG ADULT;

EID: 58149527837     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.001     Document Type: Article

References (25)

1. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52 1 (2002) 23-47
2. Aabo K., Adams M., Adnitt P., Alberts D.S., Athanazziou A., Barley V., Bell D.R., Bianchi U., Bolis G., Brady M.F., Brodovsky H.S., Bruckner H., Buyse M., Canetta R., Chylak V., Cohen C.J., Colombo N., Conte P.F., Crowther D., Edmonson J.H., Gennatas C., Gilbey E., Gore M., Guthrie D., Yeap B.Y., et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br. J. Cancer 78 11 (1998) 1479-1487
3. Cohen J.D., and Robins H.I. Hyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro. Cancer Res. 15 47(16) (1987) 4335-4337
4. Cohen J.D., Robins H.I., Schmitt C.L., and Tanner M.A. Interactions of thymidine, hyperthermia, and cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in human T-cell leukemia. Cancer Res. 49 21 (1989) 5805-5809 1
5. Cohen J.D., Robins H.I., and Schmitt C.L. Tumoricidal interactions of hyperthermia with carboplatin, cisplatin and etoposide. Cancer Lett. 44 3 (1989) 205-210
6. Cohen J.D., and Robins H.I. Thermal enhancement of tetraplatin and carboplatin in human leukaemic cells. Int. J. Hypertherm. 6 6 (1990) 1013-1017
7. Cohen J.D., Robins H.I., and Javid M.J. Sensitization of C6 glioma to carboplatin cytotoxicity by hyperthermia and thymidine. J. Neurooncol. 9 1 (1990) 1-8
8. Ohno S., Siddik Z.H., Baba H., Stephens L.C., Strebel F.R., Wondergem J., Khokhar A.R., and Bull J.M. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res. 51 11 (1991) 2994-3000
9. Tapazoglou E., Cohen J.D., Schmitt C.L., Khatana A., Sapareto S.A., and Robins H.I. Whole body hyperthermia and carboplatin: cytotoxicity for murine leukaemia and normal marrow. Br. J. Cancer 64 3 (1991) 528-530
10. Page R.L., McEntee M.C., Williams P.L., George S.L., Price G.S., Novotney C.A., Hauck M.L., Riviere J.E., Dewhirst M.W., and Thrall D.E. Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs. Int. J. Hypertherm. 10 6 (1994) 807-816
11. Wallner K.E., DeGregorio M.W., and Li G.C. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res. 46 12 Pt 1 (1986) 6242-6245
12. Robins H.I., Cohen J.D., Schmitt C.L., Tutsch K.D., Feierabend C., Arzoomanian R.Z., Alberti D., d'Oleire F., Longo W., Heiss C., et al. Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients. J. Clin. Oncol. 11 9 (1993) 1787-1794
13. D'Oleire F., Schmitt C.L., Robins H.I., Cohen J.D., and Spriggs D. Cytokine induction in humans by 41.8 degrees C whole-body hyperthermia. J. Natl. Cancer. Inst. 85 10 (1993) 833-834 19
14. Katschinski D.M., Wiedemann G.J., Longo W., d'Oleire F.R., Spriggs D., and Robins H.I. Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. Cytokine Growth Factor Rev. 10 2 (1999) 93-97
15. Robins H.I., Kutz M., Wiedemann G.J., Katschinski D.M., Paul D., Grosen E., Tiggelaar C.L., Spriggs D., Gillis W., and d'Oleire F. Cytokine induction by 41.8 degrees C whole body hyperthermia. Cancer Lett. 97 2 (1995) 195-201 6
16. Westermann A.M., Grosen E.A., Katschinski D.M., Jager D., Rietbroek R., Schink J.C., Tiggelaar C.L., Jager E., Zum Vorde sive Vording P., Neuman A., Knuth A., Van Dijk J.D., Wiedemann G.J., and Robins H.I. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur. J. Cancer 37 9 (2001) 1111-1117
17. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., Siddik Z.H., Judson I.R., Gore M.E., and Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7 11 (1989) 1748-1756
18. Robins H.I., Dennis W.H., Neville A.J., Shecterle L.M., Martin P.A., Grossman J., Davis T.E., Neville S.R., Gillis W.K., and Rusy B.F. A nontoxic system for 41.8 degrees C whole-body hyperthermia: results of a Phase I study using a radiant heat device. Cancer Res. 45 8 (1985) 3937-3944
19. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., Wheeler S., Swart A.M., Qian W., Torri V., Floriani I., Jayson G., Lamont A., and Trope C. ICON and AGO Collaborators. Lancet 361 9375 (2003) 2099-2106 21
20. Herzog T.h.J. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin. Cancer Res. 10 (2004) 7439-7449
21. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 14 (2001) 3312-3322
22. Jakobsen A., Bertelsen K., Andersen J.E., Havsteen H., Jakobsen P., Moeller K.A., Nielsen K., Sandberg E., and Stroeyer I. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J. Clin. Oncol. 15 1 (1997) 193-198
23. Richel O., Zum Vörde Sive Vörding P.J., Rietbroek R., Van der Velden J., Van Dijk J.D., Schilthuis M.S., and Westermann A.M. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer. Gynecol. Oncol. 95 3 (2004) 680-685
24. Bakhshandeh A., Bruns I., Traynor A., Robins I.H., Eberhardt K., Demedts A., Kaukel E., Koschel G., Gatzemeier U., Kohlmann T.h., Dalhoff K., Ehlers E.M., Gruber Y., Zumschlinge R., Hegewisch-Becker S., Peters S.O., and Wiedemann G.J. Ifosfamide, carboplatin and etoposide combined with 41.8 °C whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer 39 3 (2003) 339-345
25. Hegewisch-Becker S., Gruber Y., Corovic A., Pichlmeier U., Atanackovic D., Nierhaus A., and Hossfeld D.K. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Ann. Oncol. 13 8 (2002) 1197-1204